Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the safety and efficacy of tislelizumab combined
with GX regimen versus tislelizumab combined with GP regimen in the first-line treatment of
nasopharyngeal carcinoma.